INT MEDICAL (01501) · Company profile · Eqvero

INT MEDICAL

01501HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.07 bn CNY	851.95 m CNY	752.84 m CNY	585.88 m CNY	464.68 m CNY
Cost of revenue	324.46 m CNY	234.43 m CNY	267.21 m CNY	216.32 m CNY	158.71 m CNY
Research and development expense	150.06 m CNY	149.13 m CNY	125.85 m CNY	99.63 m CNY	89.96 m CNY
Selling, general and administrative expense	266.05 m CNY	200.23 m CNY	166.82 m CNY	120.68 m CNY	79.07 m CNY
Operating profit after depreciation	258.29 m CNY	212.02 m CNY	164.07 m CNY	129.34 m CNY	145.21 m CNY
Operating profit before depreciation	362.52 m CNY	291.88 m CNY	211.62 m CNY	166.42 m CNY	175.42 m CNY
EBIT	258.29 m CNY	212.02 m CNY	164.07 m CNY	129.34 m CNY	145.21 m CNY
EBITDA	362.52 m CNY	291.88 m CNY	211.62 m CNY	166.42 m CNY	175.42 m CNY
Interest expense	12.54 m CNY	2.43 m CNY	3.19 m CNY	818 k CNY	633 k CNY
Profit before tax	258.32 m CNY	213.38 m CNY	175.13 m CNY	144.47 m CNY	155.69 m CNY
Income tax expense	25.65 m CNY	23.34 m CNY	21.9 m CNY	10.64 m CNY	15.25 m CNY
Income before extraordinary items	218.79 m CNY	191.91 m CNY	156.46 m CNY	131.71 m CNY	142.96 m CNY
Common dividends	48.58 m CNY	—	47.52 m CNY	40.32 m CNY	43.16 m CNY
Total dividends	48.58 m CNY	—	47.52 m CNY	40.32 m CNY	43.16 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.